ArticleNature2019
Treatment of type 2 diabetes with the designer cytokine IC7Fc.
Article in Nature, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed, 81 citations in OpenAlex.
- Exerkines in precision management of metabolic diseases.Chinese medical journal · 2026Review
- Review
- Dysfunctional adipose tissue-lymphatic crosstalk in obesity.Nature reviews. Endocrinology · 2026Review
- The designer cytokine IC7Fc attenuates atherosclerosis development by targeting hyperlipidemia in mice.Science advances · 2025Article
- Inter-session repeatability of electroretinography and visual evoked potentials of the Celeris system.Documenta ophthalmologica. Advances in ophthalmology · 2025Article
- Article
- Adipokines: masterminds of metabolic inflammation.Nature reviews. Immunology · 2025Review
- More and more pleiotropy within the IL-6 family of cytokines.The FEBS journal · 2025Article
- Interleukin-11 receptor is an alternative α-receptor for interleukin-6 and the chimeric cytokine IC7.The FEBS journal · 2025Article
- Investigating plasticity within the interleukin-6 family with AlphaFold-Multimer.Computational and structural biotechnology journal · 2025Article
- Implications of glycosylation for the development of selected cytokines and their derivatives for medical use.Biotechnology advances · 2024Review
- IL-6R (trans-signaling) is a key regulator of reverse cholesterol transport in lipid-laden macrophages.Clinical immunology (Orlando, Fla.) · 2024Article
- Exerkines and cardiometabolic benefits of exercise: from bench to clinic.EMBO molecular medicine · 2024Review
- Exploring the serotonin-probiotics-gut health axis: A review of current evidence and potential mechanisms.Food science & nutrition · 2024Review
- IL-6 and diabetic kidney disease.Frontiers in immunology · 2024Review
- Molecular origin and biological effects of exercise mimetics.Journal of exercise science and fitness · 2024Review
- Strategies to therapeutically modulate cytokine action.Nature reviews. Drug discovery · 2023Review
- Therapeutic blockade of ER stress and inflammation prevents NASH and progression to HCC.Science advances · 2023Article
- Nerve Defect Treatment with a Capping Hydroxyethyl Cellulose/Soy Protein Isolate Sponge Conduit for Painful Neuroma Prevention.ACS omega · 2023Article
- Immunometabolism at the crossroads of obesity and cancer-a Keystone Symposia report.Annals of the New York Academy of Sciences · 2023Article
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
38 authors at 12 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The gp130 receptor cytokines IL-6 and CNTF improve metabolic homeostasis but have limited therapeutic use for the treatment of type 2 diabetes. Accordingly, we engineered the gp130 ligand IC7Fc, in which one gp130-binding site is removed from IL-6 and replaced with the LIF-receptor-binding site from CNTF, fused with the Fc domain of immunoglobulin G, creating a cytokine with CNTF-like, but IL-6-receptor-dependent, signalling. Here we show that IC7Fc improves glucose tolerance and hyperglycaemia and prevents weight gain and liver steatosis in mice. In addition, IC7Fc either increases, or prevents the loss of, skeletal muscle mass by activation of the transcriptional regulator YAP1. In human-cell-based assays, and in non-human primates, IC7Fc treatment results in no signs of inflammation or immunogenicity. Thus, IC7Fc is a realistic next-generation biological agent for the treatment of type 2 diabetes and muscle atrophy, disorders that are currently pandemic.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.